PHARMAMAR HA ACTUALIZADO FASE III LAGOON LURBINECTEDIN Y SE RETRASA SU CONCLUSIÓN HASTA ABRIL 2026. : PM060184 , El Farmaco Que le Sigue al PM01183 , En la Recta Final de la Fase I .

02 marzo 2013

PM060184 , El Farmaco Que le Sigue al PM01183 , En la Recta Final de la Fase I .

First received : February 9, 2011 .

Last updated : February 26, 2013 .

Last verified : February 2013 .

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors .

Recruitment Information

Status Recruiting

Start date 2011-01

Last follow-up date 2013-08 (Anticipated)

Primary completion date 2013-08 (Anticipated)

Organization name PharmaMar

Organization study ID PM60184-A-002-10

Sponsor PharmaMar

Health Authority United States: Food and Drug Administration